Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
暂无分享,去创建一个
M. Heymann | D. Heymann | F. Duteille | F. Gouin | J. Rousseau | F. Redini | V. Trichet | P. Perrot | E. Cassagnau | F. Deschaseaux | A-L Bouffaut
[1] M. Salgarello,et al. Autologous Fat Graft in Radiated Tissue Prior to Alloplastic Reconstruction of the Breast: Report of Two Cases , 2010, Aesthetic Plastic Surgery.
[2] Gang Li,et al. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. , 2009, Cancer letters.
[3] B. Lévy,et al. Preconditioning by Mitochondrial Reactive Oxygen Species Improves the Proangiogenic Potential of Adipose-Derived Cells–Based Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[4] D. Rose,et al. Angiogenesis, adipokines and breast cancer. , 2009, Cytokine & growth factor reviews.
[5] Rong Li,et al. Interleukin 6 Secreted from Adipose Stromal Cells Promotes Migration and Invasion of Breast Cancer Cells , 2009, Oncogene.
[6] M. Saint-Cyr,et al. Autologous fat transfer: controversies and current indications for breast surgery. , 2009, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[7] D. Banerjee,et al. Mesenchymal stem cells: flip side of the coin. , 2009, Cancer research.
[8] M. Padrines,et al. Proteases and bone remodelling. , 2009, Cytokine & growth factor reviews.
[9] E. Miot-Noirault,et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. , 2009, Cancer research.
[10] C. W. Chan,et al. Autologous fat transfer--a review of the literature with a focus on breast cancer surgery. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[11] B. Pitard,et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma , 2010 .
[12] S. Spear. Fat for breast: where are we? , 2008, Plastic and reconstructive surgery.
[13] E. Motrescu,et al. Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle , 2008, Biological chemistry.
[14] C. Jorgensen,et al. Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit? , 2008, Stem cells.
[15] J. Chirgwin,et al. Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.
[16] E. Delay,et al. [Lipomodelling for correction of breast conservative treatment sequelae. Medicolegal aspects. Expert opinion on five problematic clinical cases]. , 2008, Annales de chirurgie plastique et esthetique.
[17] E. Delay,et al. Efficacité du lipomodelage pour la correction des séquelles du traitement conservateur du cancer du sein , 2008 .
[18] E. Delay,et al. Lipomodelage et correction des séquelles du traitement conservateur du cancer du sein: Aspects médicolégaux. Le point de vue de l’expert à partir de cinq cas cliniques délicats , 2008 .
[19] A. Varan,et al. LATE RECURRENCE IN PRIMARY REGION OF PAROSTEAL OSTEOSARCOMA: A CASE REPORT , 2008, Pediatric hematology and oncology.
[20] Michael Baum,et al. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures , 2007, Nature Clinical Practice Oncology.
[21] K. Harii,et al. Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells , 2007, Aesthetic Plastic Surgery.
[22] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[23] C. Balleyguier,et al. Autologous fat transfer in reconstructive breast surgery: indications, technique and results. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[24] D. Jeon,et al. Time Dependency of Prognostic Factors in Patients with Stage II Osteosarcomas , 2007, Clinical orthopaedics and related research.
[25] N. Gallay,et al. The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities , 2007, Stem cells.
[26] E. Schwarz,et al. Clinical development of anti-RANKL therapy , 2007, Arthritis research & therapy.
[27] S. Coleman,et al. Fat Grafting to the Breast Revisited: Safety and Efficacy , 2007, Plastic and reconstructive surgery.
[28] F. Djouad,et al. Earlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem Cells , 2006, Transplantation.
[29] H. Xie,et al. Adiponectin Stimulates RANKL and Inhibits OPG Expression in Human Osteoblasts Through the MAPK Signaling Pathway , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[30] S. Ferrari,et al. Late Relapse in Osteosarcoma , 2006, Journal of pediatric hematology/oncology.
[31] M. Raffeld,et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma , 2006, The Journal of experimental medicine.
[32] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[33] David Zurakowski,et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.
[34] M. Heymann,et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.
[35] Edward W Scott,et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. , 2005, Neoplasia.
[36] H. Tsuda,et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model , 2004, Gene Therapy.
[37] Keith L. March,et al. Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells , 2004, Circulation.
[38] J. Gimble,et al. Bone and fat , 2004, Endocrine.
[39] W. Dougall,et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.
[40] J. Dennis,et al. Origin and Differentiation of Human and Murine Stroma , 2002, Stem cells.
[41] I. Holen,et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.
[42] J. Michaeli,et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] P. Kostenuik,et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. , 2001, Cancer research.
[44] S. Ferrari,et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Furukawa,et al. Microvascular Angiogenesis and Apoptosis in the Survival of Free Fat Grafts , 2000, The Laryngoscope.
[46] T. Koshino,et al. Predictive value of serum immunosuppressive acidic protein for lung metastasis after amputation of murine osteosarcoma of the lower limb. , 2000, Cancer letters.
[47] M. Padrines,et al. Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors. , 2000, Cytokine.
[48] F. Higashino,et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] S. Ferrari,et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] S. Coleman. Facial recontouring with lipostructure. , 1997, Clinics in plastic surgery.
[51] C. Emerson,et al. 10T1/2 cells: an in vitro model for molecular genetic analysis of mesodermal determination and differentiation. , 1989, Environmental health perspectives.
[52] T. Orfeo,et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.
[53] S. Pallante,et al. Complexes of organic acids with calcium phosphate: the von Kossa stain as a clue to the composition of bone mineral. , 1971, The Johns Hopkins medical journal.
[54] M. Delbaere,et al. [Efficacy of lipomodelling for the management of sequelae of breast cancer conservative treatment]. , 2008, Annales de chirurgie plastique et esthetique.
[55] D. Argyle,et al. Isolation and characterisation of cancer stem cells from canine osteosarcoma. , 2008, Veterinary journal.
[56] E. Delay,et al. [Radiological evaluation after lipomodelling for correction of breast conservative treatment sequelae]. , 2008, Annales de chirurgie plastique et esthetique.
[57] D. Heath,et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. , 2007, Cancer research.
[58] F. Djouad,et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.
[59] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] G Rosen,et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Lundy,et al. A model of tumor cell dormancy: Effects of anesthesia and surgery , 1981, Journal of surgical oncology.